GPC Biotech Presents Data on 1D09C3 Monoclonal Cancer Antibody

GPC Biotech AG has presented preclinical data on its anticancer monoclonal antibody, 1D09C3, at the 9th International Conference on Malignant Lymphoma in Lugano, Switzerland.

This conference is an international forum devoted to basic and clinical research into lymphoid tumors. 1D09C3 is currently in Phase I clinical testing. The in vivo data are derived from preclinical studies and demonstrate that 1D09C3 appears to show improved efficacy if treatment intervals are increased up to seven days. This indicates that the antibody may not need to be continuously present in the bloodstream to achieve its cell-killing effect.

The preclinical data also showed that frequent repeat treatments were not more potent than a single treatment. The tumor cells surviving the first treatment were found to become temporarily resistant to 1D09C3, with normal susceptibility resuming within about seven days. The preclinical data may be relevant in helping to determine appropriate dosing schedules for clinical studies with 1D09C3.